The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. It
is composed of extracellular domains, including a ligand-binding domain, a hydrophobic …

Despite aggressive surgical and chemotherapeutic interventions, non-small-cell lung cancer
(NSCLC) is the leading cause of cancer-related death in men and women with overall cure …

After 30 years of development, therapy with monoclonal antibodies has started to realize its
promise. Clinical use is most widespread in the field of oncology, where half of the agents …

The varying efficacy and toxicity of traditional cancer therapies has driven the development
of novel target-based agents. Members of the HER (Human Epidermal Receptor) family, in …

Epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. Its
stimulation by endogenous ligands, EGF or transforming growth factor-alpha (TGF-α) results …

Treatment of squamous cell carcinoma of the head and neck (SCCHN) has evolved greatly
in the last two decades, owing to the integration of chemotherapy, advances in …

Targeted therapies with biologic agents improved the efficacy of conventional chemotherapy
in preclinical and clinical studies. The epidermal growth factor receptor (EGFR) is a member …

Fifteen% or fewer of patients with non-small cell lung cancer (NSCLC) survive 5 years. The
current standard of care for patients with locally advanced or metastatic NSCLC is systemic …

Background Advanced squamous cell cancers of the head and neck have traditionally been
associated with high rates of morbidity and mortality. Advances in management have …

Conventional anticancer therapy using cytotoxic drugs lacks selectivity and is prone to
toxicity and drug resistance. Anticancer therapies targeting aberrant growth factor receptor …